IV Ketamine Series for MDD/PTSD: Epigenetic Clock and DNA Methylation Study (Wild Health 2024, Lexington KY)
Open-label single-arm observational study (bioRxiv preprint 2024; Wild Health, Inc., Lexington, KY; DOI 10.1101/2024.09.10.24313258). Participants: n=20 adults with moderate-to-severe MDD and/or PTSD despite prior antidepressant treatment, recruited through Wild Health clinic. Intervention: 6 subanesthetic IV ketamine infusions (0.5 mg/kg each) over 2–3 weeks; 1 participant discontinued (adverse effects), yielding 19 completers (40 paired samples). Primary endpoints: peripheral blood DNA methylation profiling (Illumina EPIC BeadChip at TruDiagnostic Labs) including epigenetic clocks (DNAmPhenoAge, GrimAge, OMICmAge, DunedinPACE, SystemsAge) and EWAS. Secondary endpoints: PCL-5, PHQ-9, and 60 clinical laboratory tests (16 participants with complete paired lab data). No control arm; no randomisation; no clinical trial registration number in methods. CT.gov: 0 hits. PubMed DataBankList: empty.
Study Arms & Interventions
Ketamine infusion series
experimentalSix subanesthetic ketamine infusions over a 2-3 week treatment course.
Interventions
- Ketamine0.5 mg/kgvia IV• six infusions over 2-3 weeks• 6 doses total
Subanesthetic dose
Primary Results(1 publication)
Participants
Adverse Events (from all publications)
| Arm / Group | n | Any TEAE | Severe | Serious | Discont. |
|---|---|---|---|---|---|
| Ketamine infusion seriesexperimental | 20 | — | — | — | 1(5.0%) |
* One participant (out of 20) discontinued the ketamine infusions due to unspecified 'adverse effects'. No other summary data for total, severe, serious, or special interest adverse events were reported in the paper.
Study Details
- StatusCompleted
- Typeinterventional
- DesignNon-randomized
- Target Enrollment20 participants
- TimelineStart: 2023-01-01End: 2024-01-01
- Compound